Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David R Strayer

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Plos One|March 21, 2012
A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist rintatolimod in severe cases of chronic fatigue syndromeDavid R Strayer, William A Carter, Bruce C Stouch, et al.
Journal of Medical Virology|September 10, 2010
Intranasal administration of adjuvant-combined vaccine protects monkeys from challenge with the highly pathogenic influenza A H5N1 virusTakeshi Ichinohe, Akira Ainai, Yasushi Ami, et al.
The Journal of Infectious Diseases|October 9, 2007
Cross-protection against H5N1 influenza virus infection is afforded by intranasal inoculation with seasonal trivalent inactivated influenza vaccineTakeshi Ichinohe, Shin-Ichi Tamura, Akira Kawaguchi, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Plos One|March 21, 2012
A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist rintatolimod in severe cases of chronic fatigue syndromeDavid R Strayer, William A Carter, Bruce C Stouch, et al.
Journal of Medical Virology|September 10, 2010
Intranasal administration of adjuvant-combined vaccine protects monkeys from challenge with the highly pathogenic influenza A H5N1 virusTakeshi Ichinohe, Akira Ainai, Yasushi Ami, et al.
The Journal of Infectious Diseases|October 9, 2007
Cross-protection against H5N1 influenza virus infection is afforded by intranasal inoculation with seasonal trivalent inactivated influenza vaccineTakeshi Ichinohe, Shin-Ichi Tamura, Akira Kawaguchi, et al.
Pageof 2